Engineered Stem Cells With Synthetic Cytokine Receptors for CIL Expansion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating cytotoxic innate lymphoid cells (CILs) from stem cells are inefficient and require the use of exogenous factors, limiting their scalability and applicability in immunotherapy.

Innovation Solution

Engineered stem cells expressing a synthetic cytokine receptor are generated using CRISPR to introduce a non-physiological ligand-binding system, allowing differentiation into CILs without exogenous factors, and are made resistant to immune rejection and rapamycin through gene disruption.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional methods are used to generate CILs from stem cells, then differentiation can occur through natural pathways, but the process is inefficient and requires multiple exogenous factors

Engineering Contradiction:

Improvedifferentiation efficiencyVSAvoidnumber of exogenous factors required

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent changes the fundamental parameter of receptor-ligand interaction by introducing a synthetic cytokine receptor that responds to a non-physiological ligand (AP21967) instead of requiring multiple physiological cytokines. This single parameter change simplifies the differentiation system from requiring multiple exogenous factors to requiring only one synthetic ligand, thereby improving productivity while reducing complexity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The synthetic cytokine receptor engineered into stem cells provides universal response to the non-physiological ligand AP21967, enabling a single factor to trigger multiple differentiation outcomes. This multi-functional approach allows one ligand to replace multiple cytokine requirements, simplifying the overall differentiation process

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Ease of operation

If stem cells are engineered to express synthetic cytokine receptors, then differentiation can be controlled by a single non-physiological ligand, but the genetic engineering process becomes more complex

Engineering Contradiction:

Improvedifferentiation controlVSAvoidgenetic engineering complexity

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The synthetic cytokine receptor acts as an intermediary component that bridges the gap between simple ligand administration and complex differentiation control. By introducing this intermediate element into the stem cells, the system achieves easy operational control through a single ligand while managing the genetic engineering complexity through a well-defined receptor structure

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The genetic engineering is performed in advance to incorporate the synthetic cytokine receptor into stem cells before differentiation. This preliminary action establishes the controlled differentiation capability upfront, allowing simple ligand-based control during the actual differentiation process without repeating complex engineering steps

Inventive Principle:

Principle #10Preliminary action

3Quantity of substance

If CILs are expanded using traditional cytokine methods, then cell proliferation can occur, but the expansion requires multiple exogenous cytokines and is costly

Engineering Contradiction:

ImproveCIL cell quantityVSAvoidexogenous cytokine consumption

Core Design Contradiction:

Quantity of substanceVSLoss of substance

Solution Approach 1:

The engineered CILs express the synthetic cytokine receptor that responds to the non-physiological ligand AP21967, enabling them to self-regulate their expansion in response to a single exogenous factor. This self-service capability reduces dependence on multiple external cytokines, decreasing substance loss and cost while maintaining high cell quantity production

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The expansion system changes from requiring multiple cytokine parameters to responding to a single non-physiological ligand parameter. This parameter simplification dramatically reduces the amount of exogenous substances needed while achieving equivalent or superior cell expansion quantities

Inventive Principle:

Principle #35Parameter changes

4Reliability

If stem cells are differentiated into CILs using sequential pathways, then proper lineage development can occur, but the process takes extended time and multiple steps

Engineering Contradiction:

Improvelineage differentiation accuracyVSAvoiddifferentiation time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The differentiation process uses periodic application of the non-physiological ligand AP21967 to drive sequential lineage development. By applying the single ligand at different time points and concentrations, the system achieves reliable lineage differentiation while reducing total time compared to traditional continuous multi-factor approaches

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20250367290A1Engineered stem cells and uses thereof

Publication Date: 2025.12.04 UMOJA BIOPHARMA INC

AI summary

Provided are compositions and methods for a cell population comprising engineered stem cells comprising a synthetic cytokine receptor for a non-physiological ligand. The non-physiological ligand activates the synthetic cytokine receptor in the engineered stem cells to induce differentiation of the stem cells and, expansion and/or activation of resulting cytotoxic innate lymphoid cells.